Pharmacologic class (EPC) · 3 drug pages

Vinca alkaloid: adverse event reports filed with FDA

33,176 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

33,176
reports across the class: 0.2% of all reports; 1,735
reports, 12 months to June 2026: 2,428 in the 12 months before; 97.2%
marked serious by the reporter: 57.4% across all reports; 3
drugs with a page: brand and generic names counted separately

Vinca alkaloid is a pharmacologic class (an FDA Established Pharmacologic Class) with 3 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 33,176 adverse event reports received by FDA, 0.2% of the database, from January 2004 to June 2026.

1,735 reports arrived in the 12 months to June 2026, down 29% from 2,428 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 97.2% of the class's reports are marked serious, 18.4% record death among the outcomes and 45.6% record hospitalisation, as reported.

Across the class the reactions recorded most often are febrile neutropenia (13.9%), neutropenia (7%) and off label use (6.3%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Vincristine sulfate	generic	26,262	1,392	96.9%	Febrile neutropenia
Vinorelbine	generic	5,307	247	98.4%	Disease progression
Vinblastine sulfate	generic	1,607	96	97.3%	Febrile neutropenia

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Febrile neutropeniafever with low white blood cells13.9%4,623
Neutropenialow neutrophils, a type of white blood cell7%2,334
Off label useused for a purpose or in a way not on the label6.3%2,106
Pyrexiafever6.3%2,105
Disease progressionthe disease advanced4.7%1,559
Nauseafeeling sick4%1,318
Vomitingbeing sick3.8%1,273
Sepsisa severe body-wide response to infection3.6%1,189
Drug ineffectivethe medicine did not work as expected3.6%1,179
Anaemialow red blood cells3.5%1,174
Thrombocytopenialow platelets3.3%1,111
Diarrhoealoose or frequent stools3.3%1,101
Pneumonialung infection3.2%1,048
Pancytopenialow counts of all blood cells3.1%1,045
Deaththe patient died; cause not stated by this term2.8%941
Malignant neoplasm progression2.8%934
Product use in unapproved indicationused for a purpose not on the label2.6%867
Fatiguetiredness2.6%864
Hypotensionlow blood pressure2.6%863
Neuropathy peripheralnerve damage in hands or feet2.6%859
Abdominal painstomach or belly pain2.4%809
Mucosal inflammation2.4%800
White blood cell count decreasedlow white cell count2.3%779
Myelosuppression2.3%773
Interstitial lung diseasescarring or inflammation of lung tissue2.3%766

Solid bar: share of all class reports. Hollow bar: the median share across the 3 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death18.4%6,090

Life-threatening8.8%2,934

Hospitalisation (initial or prolonged)45.6%15,125

Disability1.6%519

Congenital anomaly0.2%62

Other serious56.7%18,807

Not serious2.8%942

Patient age

Under 22.3%771

2 to 1113.4%4,430

12 to 176.7%2,219

18 to 4413.3%4,422

45 to 6418.5%6,135

65 to 7410.8%3,568

75 and over5.5%1,828

Age not given29.5%9,803

Who reported

Physician39.1%12,967

Pharmacist6%1,991

Other health professional39%12,953

Lawyer0%15

Consumer or non-health professional6.5%2,155

Not given9.3%3,095

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Vinca alkaloid reports

Which drugs are in the Vinca alkaloid class on this site?

Vincristine sulfate, Vinorelbine and Vinblastine sulfate. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

33,176 reports through June 2026, 1,735 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

febrile neutropenia (13.9%), neutropenia (7%), off label use (6.3%), pyrexia (6.3%) and disease progression (4.7%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.